Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients

Abstract Background Ertapenem, a group I carbapenem antibiotic, has been shown to be safe and effective in treating adults with complicated intra-abdominal (cIAI) or acute pelvic infection (API). This study evaluated ertapenem for treating these infections in children. Methods In an open-label study...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2007-09, Vol.194 (3), p.367-374
Main Authors: Yellin, Albert E., M.D, Johnson, Jeffrey, M.D, Higareda, Iliana, M.D, Congeni, Blaise L., M.D, Arrieta, Antonio C., M.D, Fernsler, Doreen, B.S, West, Joseph, Ph.D, Gesser, Richard, M.D
Format: Article
Language:English
Subjects:
Abdomen
Abdominal Cavity
Abortion
Acute Disease
Acute pelvic infection
Adolescent
Age
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Appendicitis
Bacterial Infections - drug therapy
beta-Lactams - therapeutic use
Biological and medical sciences
Child
Child, Preschool
Clavulanic Acids - therapeutic use
Drug dosages
Drug therapy
E coli
Ertapenem
Female
General aspects
Hospitals
Humans
Intra-abdominal
Male
Medical sciences
Pain
Pediatric
Pelvis
Pharmacology. Drug treatments
Prospective Studies
Surgery
Teenagers
Ticarcillin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Ertapenem, a group I carbapenem antibiotic, has been shown to be safe and effective in treating adults with complicated intra-abdominal (cIAI) or acute pelvic infection (API). This study evaluated ertapenem for treating these infections in children. Methods In an open-label study, children aged 2 to 17 years with cIAI or API were randomized 3:1 to receive ertapenem or ticarcillin/clavulanate. Children 13 to 17 years of age received 1 g parenterally daily, and those 2 to 12 years of age received 15 mg/kg twice daily. Patients
ISSN:0002-9610
1879-1883
DOI:10.1016/j.amjsurg.2007.01.023